Crosley CRSH268MW2 Bedienungsanleitung Seite 53

  • Herunterladen
  • Zu meinen Handbüchern hinzufügen
  • Drucken
  • Seite
    / 88
  • Inhaltsverzeichnis
  • LESEZEICHEN
  • Bewertet. / 5. Basierend auf Kundenbewertungen
Seitenansicht 52
4 Results
challenged intravenously with 3 x 10
7
CFU of S. aureus strain ATCC 29213 one week after
the second booster immunisation. For two weeks infected mice were monitored daily for
clinical signs of infection and mortality. Mice immunised with BSA as non-specific antigen
served as control.
As shown in Figure 4.14, 60 % of the mice immunised with either BT1 (A) or BT3 (C)
survived, in contrast to only 25 % surviving mice in the group of BSA-immunised mice. In
case of immunisation with recombinant BT2 (B) no improved survival compared to infected
control mice was observed.
To ascertain, whether immunisation with both candidates could potentiate the observed
protective effect, mice were immunised with a mixture of equal amounts of each antigen,
resulting in a serum titre comparable to single immunisation or BSA as control. As shown in
Figure 4.15, more than 65 % of the mice immunised with BT1 alone (A) survived the chal-
lenge with S. aureus in contrast to only 10 % in the BSA control group. In mice immunised
with BT3 (B) still 30 % more animals survived the challenge compared to BSA immunised
mice. In case of immunisation with a mix of recombinant BT1 and BT3 (C) the survival
rate further declined to 30 %, thus just 20 % higher than observed for mock immunised
mice. The discrepancy between single target immunisation and the bivalent immunisation
could be due to the lower amount of antigen used for immunisation, since only half of the
amount of each antigen was used for immunisation. Thus, the conditions for polyvalent
immunisations have to be further improved.
Altogether, three of the so far characterised proteins, namely hp2160, BT1 and BT3,
conferred protection in a murine model of sepsis. The remaining candidates will now be
tested consecutively, to enable the formulation of a multivalent mix of vaccine candidates
for active immunisation in order to improve the protective effects observed upon monovalent
immunisation.
53
Seitenansicht 52
1 2 ... 48 49 50 51 52 53 54 55 56 57 58 ... 87 88

Kommentare zu diesen Handbüchern

Keine Kommentare